
Pyxis Oncology (PYXS) Stock Forecast & Price Target
Pyxis Oncology (PYXS) Analyst Ratings
Bulls say
Pyxis Oncology Inc. has demonstrated a positive shift in its Phase of Success (PoS) for its MICVO 2/3L HNSCC program, reflecting increased confidence due to an updated data disclosure plan that promises to de-risk the project if the objective response rate (ORR) benchmark is achieved. The impending MICVO phase 1 data update scheduled for 4Q25 is expected to provide crucial insights regarding the company’s competitive standing within hard-to-treat cancer markets, potentially influencing long-term strategic decisions and investment attractiveness. Additionally, while the company has not factored in potential royalties from net sales in China, the prospect of receiving mid-to-high single-digit percentage royalties represents an additional upside that could enhance its financial outlook.
Bears say
Pyxis Oncology Inc. faces significant downside risks that may adversely affect its financial stability and stock performance, including the potential lack of efficacy or safety concerns related to its lead candidate, MICVO. Additionally, unforeseen delays in research and development, regulatory approvals, or commercialization efforts could hinder progress and escalation of costs. The competitive landscape in the head and neck squamous cell carcinoma (HNSCC) space, combined with the possibility of insufficient capital for ongoing research activities, further exacerbates the company’s financial vulnerabilities.
This aggregate rating is based on analysts' research of Pyxis Oncology and is not a guaranteed prediction by Public.com or investment advice.
Pyxis Oncology (PYXS) Analyst Forecast & Price Prediction
Start investing in Pyxis Oncology (PYXS)
Order type
Buy in
Order amount
Est. shares
0 shares